Enasidenib
| CAS No. | 1446502-11-9 |
|---|---|
| MDL No. | MFCD29472245 |
| MF | C19H17F6N7O |
| MW | 473.40 |
| InChI Key | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Enasidenib is a 1,3,5-triazine substituted with (2-hydroxy-2-methylpropyl)nitrilo at position 2, 6-(trifluoromethyl)pyridin-2-yl at position 4, and [2-(trifluoromethyl)pyridin-4-yl]nitrilo at position 6. It is an IDH2 inhibitor approved for treating adults with relapsed or refractory AML. It functions as an antineoplastic agent and EC 1.1.1.42 inhibitor. It is classified as an aminopyridine, organofluorine compound, secondary amino compound, tertiary alcohol, member of 1,3,5-triazines, and aromatic amine.
| CAS No. | 1446502-11-9 |
|---|---|
| Product Name | Enasidenib |
Biological Targets
IDH2
Associated Conditions
myeloid leukemia·hematopoietic and lymphoid cell neoplasm·cancer·multiple myeloma·acute myeloid leukemia·
* The information provided here is compiled from public sources and is for reference only.
